Tom Fielding
Metabolic Desk
People on or considering GLP-1s and serious about weight loss
Tom Fielding leads the Metabolic Desk, making sense of the GLP-1 era — Ozempic, Wegovy, appetite and metabolic health — in clear, non-judgmental language. He focuses on what the evidence shows and the questions worth asking a clinician.
Latest articles
Obesity as an Accelerator of Cardiovascular Aging — And Why Weight Loss May Buy You Time
A major European Heart Journal review reframes excess weight as a driver of the heart's biological aging itself. The implication: weight reduction may be less about preventing one bad day and more about extending healthy years.
The Mind–Cancer Link: Why Depression After Diagnosis May Raise Mortality by Up to 83%
A 2025 meta-analysis of 65 studies finds that depression following a cancer diagnosis is associated with substantially higher mortality — strengthening the case for mental-health screening inside oncology.
Beyond Weight Loss: What the Latest GLP-1 Evidence Says About Liver, Kidney, Heart, and Cost
Fresh 2025 reviews map semaglutide's reach into fatty liver disease, cardiovascular risk, kidney protection — and the economics of treating obesity at scale. The signals are real, but the picture is still filling in.
The GLP-1 Pipeline: Triple Agonists, Older Adults, and the Cautious Move Toward Type 1
A wave of 2025 reviews and trial analyses sketches what comes after tirzepatide — broader populations, bigger weight-loss numbers, and tentative steps into autoimmune diabetes.
Obesity as an Immune Disease: Why Inflammation May Be the Missing Frame
A major new synthesis argues obesity is not just a metabolic condition but a fundamentally altered immunological state — reshaping how we think about GLP-1s, weight loss, and the body's defenses.
GLP-1 Reality Check: Doctors Underestimate the Upside, Patients Underuse the Drugs
New survey and claims data suggest a quiet mismatch in cardiometabolic care: physicians may be undercounting how much weight and risk these drugs move, while many eligible adults never start them.
Diabetes, the Liver, and the Quiet March of MASLD
A three-year cohort of type 2 diabetics tracked who silently progressed to liver fibrosis — and which routine lab markers offered the earliest warning.
Sitting Still: How Sedentary Time Became a Measurable Cancer Risk
A new wave of population-level research is moving the link between chair-time and cancer from slogan to statistics — and reframing movement as a quiet prevention lever for desk-bound lives.